Company Profile
Barinthus Biotherapeutics Stock Price, News & Analysis
- Ticker:
- BRNS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United Kingdom
Stock performance
0.56 USD (-0.89%)
Close
Last updated: August 6, 2026
27M USD
Market cap
Why the stock is moving
The latest company update was “Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate Developments”. BRNS changed 0.89% and closed at $0.5650 on Aug 6, 2026, indicating a relatively limited closing-price reaction to this earnings update.
Company overview
Immune-Tolerance Therapeutics
Barinthus Biotherapeutics develops immunotherapies intended to retrain the immune system in autoimmune and chronic infectious diseases. Its current internal focus is immune tolerance rather than broad immune stimulation.
SNAP-TI Platform
The SNAP-Tolerance Immunotherapy platform is designed to deliver disease-relevant antigens in a way that promotes antigen-specific immune tolerance. This approach seeks to suppress harmful immune responses without broadly compromising immune function.
VTP-1000
VTP-1000 is the lead SNAP-TI candidate and is being evaluated in the Phase 1 AVALON trial for celiac disease. The multiple-ascending-dose portion includes a gluten challenge after three doses to assess biological and clinical effects.
Future catalysts
Multiple-ascending-dose data from the Phase 1 AVALON trial of VTP-1000 expected in the second half of 2026.
Recent news
- 01
Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate Developments
Source: Barinthus Biotherapeutics
- 02
Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments
Source: Barinthus Biotherapeutics
- 03
Barinthus Bio Reports Full Year 2025 Financial Results and Updates on Corporate Developments
Source: Barinthus Biotherapeutics
- 04
Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
Source: Barinthus Biotherapeutics
- 05
Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate Developments
Source: Barinthus Biotherapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Barinthus Biotherapeutics (BRNS)?
Barinthus Biotherapeutics (BRNS) most recently closed at 0.56 USD, a -0.89% move versus the previous session.
What is the market cap of Barinthus Biotherapeutics (BRNS)?
Barinthus Biotherapeutics currently has a market capitalization of 27M USD on BioPharmSignal.
What does Barinthus Biotherapeutics do?
Immune-Tolerance Therapeutics Barinthus Biotherapeutics develops immunotherapies intended to retrain the immune system in autoimmune and chronic infectious diseases. Its current internal focus is immune tolerance rather than broad immune stimulation. SNAP-TI Platform The SNAP-Tolerance Immunotherapy platform is designed to deliver disease-relevant antigens...
On which exchange is BRNS stock listed?
Barinthus Biotherapeutics (BRNS) is associated with NASDAQ, United Kingdom, Biopharma.
What is SNAP-TI?
SNAP-TI Platform The SNAP-Tolerance Immunotherapy platform is designed to deliver disease-relevant antigens in a way that promotes antigen-specific immune tolerance.
Which conditions is Barinthus Biotherapeutics targeting with SNAP-TI?
Immune-Tolerance Therapeutics Barinthus Biotherapeutics develops immunotherapies intended to retrain the immune system in autoimmune and chronic infectious diseases. Its current internal focus is immune tolerance rather than broad immune stimulation. SNAP-TI Platform The SNAP-Tolerance Immunotherapy platform is designed to deliver disease-relevant antigens...
How does Barinthus Biotherapeutics describe recent progress with SNAP-TI?
Multiple-ascending-dose data from the Phase 1 AVALON trial of VTP-1000 expected in the second half of 2026.
What is VTP-1000?
VTP-1000 VTP-1000 is the lead SNAP-TI candidate and is being evaluated in the Phase 1 AVALON trial for celiac disease.